Sarcopenic Obesity: Estimation of Prevalence and Identification of Clinical and Biological Determinants in a Population of Adult Obese Patients

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03394469

Acronym

OBESAR

Enrollment

800

Registered

2018-01-09

Start date

2018-06-04

Completion date

2020-06-06

Last updated

2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity, Sarcopenia

Brief summary

This project aims first to determine the prevalence of sarcopenia in a population of obese people of extended age group (18-70 years). In a second step, the factors determining and / or predisposing to sarcopenic obesity will be identified as well as plasmatic and urinary biomarkers specific to this phenotype.

Detailed description

Collection of clinical and paraclinical data (biological and anthropometric) for evaluation of sarcopenic obesity in obese patients. Biological collection to identify plasma, serum, genetic, urinary and faecal biomarkers associated with sarcopenic obesity

Interventions

OTHERcollection

Blood, urinary and faecal samples

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Masking description

No masking

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Age: 18-70 years * Sex: men and women * Patient followed in clinical nutrition benefiting from a metabolic assessment for optimization of clinical and paraclinical management * Patient meeting the criteria of obesity defined by BMI\> 30 kg / m² * Major patient with free, informed and signed consent * Patient covered by the social security scheme

Exclusion criteria

* Patient with cancer or severe chronic disease (renal failure, respiratory failure, liver failure) * Patient with neuromuscular disease * Patient with a total inability to walk * Minor patient * Refusal of the patient to participate in the study * Pregnant or lactating women * Patient deprived of liberty or under guardianship.

Design outcomes

Primary

Measure	Time frame	Description
Sarcopenia	at day 1	The primary endpoint is sarcopenia (present / absent), defined using the muscle mass index (SMI) corresponding to = SM / Height², where the total muscle mass (SM) is calculated from validated equations. by Janssen et al in a population of men and women with a large age range (18-86 years) and adiposity (BMI: 16-48 kg / m integrating bio-impedancemetry data ( BIA).

Countries

France

Contacts

Primary ContactPatrick LACARIN

placarin@chu-clermontferrand.fr0473751195

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026